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Charles Auffray1*, Timothy Caulfield2, Julian L. Griffin3,4, Muin J. Khoury5, James R. Lupski6,7
and Matthias Schwab8,9,102015 has been an exciting year for genomic medicine.
We asked our Section Editors to discuss the break-
throughs in their fields of expertise, and what these
might mean for the future. As in previous years, exome
and whole-genome sequencing are leading the way in
our understanding of disease mechanisms, their diagno-
sis and treatment, while information about the protein
products of the genome has also grown, driven by novel
technological advances. Precision medicine is now taking
off as an important topic in the public health sphere and
in education, and no discussion of 2015 would be
complete without a mention of the huge advances in
gene editing technologies, the implications of which
have dominated ethics and policy debate.Clinical genomics for functional annotation of the
human genome
Functional annotation of the human genome through
gene discovery took a notable “leap” in 2015 with insight
into gene function provided using Mendelian genomics
approaches, primarily exome sequencing, to study the spe-
cific rare variants underlying disease trait manifestation.
The numbers of gene discovery publications are too nu-
merous to single out any one; however, the UK Wellcome
Trust Deciphering Developmental Disorders (WTDDD)
[1, 2] and US National Human Genome Research Institute
Centers for Mendelian Genomics (NHGRI CMG) [3] ini-
tiatives and other such efforts around the world are having
a noticeable impact with direct and immediate clinical
practice implications. The global impact of this work on
human genetics, genomics and the practice of clinical
medicine is palpable. Personal genome information and
individual variation based on whole exome studies is in-
creasingly utilized to identify a molecular diagnosis and
help formulate a differential clinical diagnosis, particularly* Correspondence: cauffray@eisbm.org
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diagnosis by conventional clinical approaches. Genome
Medicine dedicated an entire issue (July 2015) to this topic
with notable papers describing advances in emergency
medical genomes [4] and reviewing the integration of clin-
ical phenotypic information into the analyses of whole ex-
ome study data [5].
This effort to functionally annotate the human genome
has been greatly facilitated by a web-based platform for
rare disease gene discovery—the Matchmaker Exchange
[6]—that has enabled the worldwide connection of fam-
ilies with rare diseases and the clinicians caring for them
to contribute to this effort for humanity. Such rare variant
studies are also beginning to yield insights into complex
traits such as scoliosis and neuropathy, and the genetic
architecture and genetic models potentially underlying
common and complex traits including compound inherit-
ance [7] and mutational burden [8].
As we look forward in 2016 the clinical data available
that may enhance biological research efforts will likely
continue to explode. More and more we may find that
model organism studies look toward human genetics
and medical genetics data to provide important insights
into biology and in so doing reveal fundamental under-
standing of disease processes. Moreover, such new un-
derstanding may foment novel approaches to disease
management and potentially enable therapeutic inter-
vention for rare variant associated disease.
James R. Lupski,
Section Editor,
Genomics and epigenomics of diseaseImplementation of pharmacogenomics and
beyond
There is increasing awareness of pharmacogenomics
(PGx) as a key component in personalized medicine. A
recent evaluation of all 517 medications labeled by the
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clude PGx information which covers pharmacokinetic (for
example, drug metabolism/transport) and pharmacody-
namic targets [9]. Warnings are related to therapeutic in-
dications, posology and method of administration, and
contraindications, thereby directly influencing treatment
decisions. Predominantly anticancer drugs are affected by
these PGx labels.
Major efforts have been initiated to implement genetic
testing of actionable pharmacogenes into clinical practice.
The Clinical Pharmacogenetics Implementation Consor-
tium (CPIC), a group of international experts, is working
on evidence-based guidelines which are standardized and
provide PGx data to individualize the prescribing of drugs
[10]. However the clinical implementation process is
hampered by several issues such as the reluctance of pro-
fessional societies, clinicians, and reimbursement organi-
zations. One major concern is the strict request for
prospective controlled clinical trials demonstrating state-
of-the art evidence for the superiority of an individualized
approach for drug prescription based on pharmacogenetic
testing. Regarding this issue, a landmark randomized
clinical trial has been published corroborating the clin-
ical utility of upfront genetic testing for the thiopurine
S-methyltransferase gene TPMT to avoid hematotoxi-
city associated with thiopurine drugs, such as azathioprine
[11]. Convincing evidence had already been established in
the 1990s that patients with decreased thiopurine methyl-
transferase enzyme activity and standard dosing of thio-
purines are at risk of developing myelosuppression.
Nevertheless the progress of clinical implementation is
still slow and hopefully will derive benefit from this recent
trial. Another example is dihydropyrimidine dehydrogen-
ase (DPYD) PGx and drug use of fluoropyrimidines (for
example, fluorouracil). Just 30 years after the first descrip-
tion of fatal outcome of fluorouracil administration due to
DPYD deficiency, a meta-analysis in 2015 has provided
strong evidence that several rare DPYD variants contribute
to fluoropyrimidine-induced severe toxicity [12]. Although
fluoropyrimidines are frequently prescribed, DPYD testing
is still not officially recommended [10].
The vision of personalized medicine and PGx is rather
complex and strategies are needed for better clinical imple-
mentation. The use of electronic clinical decision support
(eCDS) like the US-initiative eMERGE (Electronic Medical
Records and Genomics) will promote the progress of clin-
ical implementation of PGx. However comprehensive and
systematic phenotypic characterization of the patient, in-
cluding diseases and drug therapy, by high-throughput
technologies is mandatory. Computer-based, direct inter-
view methods are available to assess the patients’ pheno-
types independent of physician input in a standardized
manner [13]. Multi-omics data in addition to genomic in-
formation which may improve prediction of drug responsewill be routinely available in the near future. Thus
systems-based approaches and drug-specific algorithms
are required, a concept which is beyond eCDS tools.
The translational, multidisciplinary, and facilitative role of
clinical pharmacology may help to achieve this goal [14].
Matthias Schwab,
Section Editor,
Pharmacogenomics and personalized medicine
The beginning of precision medicine for
population health
In 2015, the USA launched the precision medicine ini-
tiative that includes two components: one focusing on
cancer genomics and treatment, and one focusing on
generating data on long-term health and disease in a
national cohort research study of one million or more
people [15]. While much of this initiative will take years
to develop outputs for use in healthcare, a public health
perspective is crucial to ensure the initiative’s success in
terms of representativeness, generalizability, implementa-
tion, and near-term deployment of already established
evidence-based genomic findings to save lives and prevent
disease [16].
The field of pathogen genomics continues to expand.
Molecular technologies are being integrated into the diag-
nosis, treatment, and control of infections. For example,
rapid metagenomic identification of viral pathogens in
clinical samples can be accomplished by real-time nano-
pore sequencing analysis [17]. The Centers for Disease
Control and Prevention (CDC) Advanced Molecular De-
tection initiative is combining genome technologies with
bioinformatics and epidemiology to enhance public health
surveillance, investigations, and control of infectious dis-
eases [18]. Pathogen genomics is becoming quite helpful
globally; for example, in tracking the Ebola virus epidemic
transmission in West Africa [19].
We also saw increasing applications of human genetics
into public health programs. While genetics has been
part of public health since newborn screening began in
the 1960s, genetics is becoming a priority area for pre-
vention and treatment of common chronic diseases such
as cancer and heart disease. A special 2015 issue of the
journal Healthcare, focusing on implementation of pub-
lic health genomics, presented data and information on
a range of ongoing public health activities, including redu-
cing the burden of hereditary breast and ovarian cancer,
screening children for familial hypercholesterolemia, and
engaging medically underserved populations in family his-
tory education [20].
Because of the rapid evolution of genomic medicine,
a crucial function in public health genomics is to iden-
tify evidence-based genomic applications that can im-
prove health, inform and engage various stakeholders,
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grams [21]. To help with this daunting task, the CDC
launched in 2015 the Public Health Genomics Know-
ledge Base in an effort to continue capturing evolving
snapshots of the field while tracking the translational
trajectory of genome-based discoveries into population
health impact [22].
While the precision medicine initiative will take years
to mature and lead to tangible discoveries and products,
2016 promises to be an exciting year for the intersection
of precision medicine and population health. Some key
areas to watch include: (1) developing more robust ap-
proaches to obtain empirical data on the impact of gen-
omics and precision medicine on population health; (2)
developing metrics for best practices on genomics and
population health including indicators for successful
implementation and outcomes; and (3) exploring key
concepts for the development of “precision public
health” [23] beyond genomics, to include a variety of




Genomic epidemiology and public health genomicsThe view from the proteome, metabolome, and
lipidome: life at the end of the central dogma
I have chosen four articles published in 2015 that I feel
either demonstrate the versatility of proteomic, meta-
bolomic, or lipidomic approaches to medicine, or will
have significant impacts as new approaches in the near
future.
While liquid chromatography mass spectrometry (LC-
MS) dominates as a tool for both metabolomics and pro-
teomics, users have to decide whether they will perform
nontargeted, discovery approaches, which are at best
semiquantitative in nature, or targeted approaches rely-
ing on triple quadrupole MS, which, while quantitative,
only target a limited number of metabolites or peptides.
Developments in 2015 have questioned these separate
workflows. Guo and colleagues [24] describe an ap-
proach, termed sequential window acquisition of all the-
oretical fragment ion spectra (SWATH)-MS, to acquire
the parent ion and fragmentation data of peptides pro-
duced from a tissue biopsy by varying the precursor iso-
lation window in a sequential manner. Mass transitions
associated with individual peptides are reconstructed in
silico and produce spectra comparable to that acquired
with a triple quadrupole in terms of specificity but with
the global nature of a nontargeted approach. They illus-
trate this by detecting over 2000 proteins in biopsy sam-
ples from patients with renal cell carcinoma.Similar approaches can be used to reconstruct lipi-
domes, using the fact that all lipid species consist of a
series of building blocks such as individual fatty acids
and head groups. Ni and coworkers [25] describe a novel
application to identify carbonylated lipid peroxidation
products, which may be useful as biomarkers of a range
of diseases including atherosclerosis, fatty liver disease,
and reperfusion injury, using LipidXplorer software.
One problem with new bioinformatic tools that limits
their uptake is that they may be written in a variety of
languages. Giacomoni and coworkers [26] borrow an ap-
proach from genomics to develop a web-based workflow
for LC-MS-based metabolomics that links software from
a variety of sources. Workflow4Metabolomics provides a
virtual research environment built upon the Galaxy envir-
onment [27] linking together open source tools that allow
users to completely process their data without extensive
experience of the software or tools.
Metabolomics, proteomics, and lipidomics are also de-
livering in terms of translational medicine. For example,
Eiden and colleagues [28] used LC-MS-based lipidomics
to identify biomarkers associated with a failure of adi-
pose tissue function in lipodystrophic patients. They
identified a characteristic alteration in triglyceride pro-
files caused by increased de novo lipogenesis in the liver
as a consequence of ectopic fat deposition which may be
applicable to identifying those with fatty liver in the gen-
eral population. With new developments in tools and
software we should see the range of these metabolomic,
proteomic, and lipidomic biomarkers expand and make
it into the clinic.
Julian L. Griffin,
Section Editor,
Proteomics & metabolomics in medicine
Big data and genomic medicine converge to
support personalized medicine globally
2015 has witnessed an acceleration of the convergence of
big data and genomic medicine that supports the imple-
mentation of personalized medicine using systems biology
approaches. These are now being developed globally
through advanced education programs targeted at re-
search and healthcare professionals as well as the public.
These trends were discussed at the Big Data and
Healthy Living Technologies Roundtable organized by
BioHealth Computing and the European Scientific Insti-
tute, the training branch of CERN, in Archamps, France
[29], and during the Big Data in Health Care—Challenges,
Innovations and Implementation symposium organized
by the Luxembourg Centre for Systems Medicine in
Munsbach, Luxembourg [30]. On these two occasions,
it became clear that, firstly, the real-life implementation of
systems medicine to address important unmet healthcare
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generation of scientists and medical doctors, and, sec-
ondly, that decades of expertise developed in other fields
such as particle physics are available to support the devel-
opment of open standards for the description and ex-
change of the variety of big data in health.
In relation to the first issue, Siwo et al. highlighted
[31] how cloud-computing and genetic testing are being
combined in structured education programs to leverage
the large genetic variation existing in Africa, thus
bringing the continent to the forefront to explain geno-
type–phenotype–disease relationships. The participants
from academic, industrial and governmental organiza-
tions also recognized that the current inability to deal
with the second widely debated issue, as discussed by
Horvitz and Mulligan [32], may constitute a major
roadblock in the development of personalized medicine
internationally. Indeed, the diversity of legal and regula-
tory frameworks and the invalidation by the European
Court of Justice of the United States Safe Harbor provi-
sions for data transfer across the Atlantic [33] are intro-
ducing a high level of uncertainty. In this context, the
introduction by Bahr and Schlünder [34] of a code of
practice for the secondary use of medical data in scientific
research projects, and its consideration in the ongoing
revision of the European Directive on Personal Data
Protection, may provide a path toward harmonization of
regulatory practices.
Through the consolidation of these trends, 2016 should
therefore see more advances toward the actual implemen-
tation of participatory, preventive, predictive, personalized
(P4) systems medicine to understand wellness and tackle
unmet medical needs worldwide.
Charles Auffray,
Section Editor,
Systems medicine and informatics
Gene editing dominates science policy debates
While many genomic policy issues continue to attract
significant attention from both the academic community
and the general public, the social and ethical challenges
associated with the new gene-editing technology domi-
nated in 2015.
The prospect of being able to efficiently edit the hu-
man genome—through the application of a technology
known as CRISPR-Cas9—has stirred debate about if and
when the modification of the human germ line can ever
be ethically justified. Some in the ethics community have
called for a complete ban, fearing, inter alia, the unknown
future consequences of altering the human genome.
Those who support the cautious clinical application of
gene editing note the potential to cure rare monogenic
diseases [35]. The debate culminated in an internationalscientific summit held in Washington DC at the National
Academy of Sciences, where it was suggested that research
should continue but—at least for now—a clinical applica-
tion should not be attempted until governance, safety, and
efficacy issues are resolved [36]. This was, in effect, a call
for a voluntary moratorium on edits that could be inher-
ited but also support for the research to continue. This
conclusion fits with recommendations made by other en-
tities, such as the International Society for Stem Cell Re-
search and the Hinxton Group [37]. It should be noted
that in some jurisdictions there are already laws in place
that would have an impact on the clinical application of
the emerging gene-editing technology. In my home coun-
try of Canada, for example, any procedure that results in
the alteration of the germ line, even if done to cure a
disease like Tay Sachs or Huntington’s, could be catego-
rized as a criminal offence as per the relevant federal
law [38]. Given the ongoing debate about the potential
scientific and health benefits, the Canadian situation
highlights the potential policy dilemmas created by the
use of rigid legislative frameworks to regulate unpre-
dictable areas of science.
Another policy challenge that received attention in 2015
was the regulation of direct-to-consumer (DTC) genetic
testing. In 2013, the California company 23andMe was
prohibited by the US Food and Drug Administration from
providing health-oriented testing to its consumers. But in
2015, the company was granted permission to start pro-
viding a limited array of services (for example, providing
information about “carrier status” for conditions like
sickle-cell anemia and cystic fibrosis) [39], thus once again
prompting questions about the potential health value (if
any) and risks (if any) of these kinds of DTC services.
2016 will undoubtedly see the emergence of new eth-
ical challenges, such as the regulation of the noninvasive
prenatal testing market and the growing (and largely
evidence-free) DTC genetic testing industry for lifestyle,
fitness, and nutrition. But as the science continues to
move forward quickly, gene editing seems likely to re-
main a dominant policy issue in 2016.
Timothy Caulfield,
Section Editor,
Ethical, legal and social issues
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